Background Pancreatic cancer (PC) is a highly fatal malignancy with few effective therapies
currently available. Recent studies have shown that PD-L1 inhibitors could be potential …

Inhibiting the functioning of PD-1/PD-L1 to activate human immune system and improve the
prognosis of pancreatic cancer (PC) would provide a significant boost to handling the …

Despite the substantial impact of post-translational modifications on programmed cell death
1 ligand 1 (PD-L1), its importance in therapeutic resistance in pancreatic cancer remains …

Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant tumour with an extremely
poor prognosis due to its insidious initiation and a lack of therapeutic strategies. Resveratrol …

Immunotherapy is one of the most promising strategies for cancer, compared with traditional
treatments. As one of the key emerging immunotherapies, anti-PD-1/PD-L1 treatment has …

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers and is the third
highest among cancer related deaths. Despite modest success with therapy such as …

Background Pancreatic cancer (PC) hijacks innate cellular processes to promote cancer
growth. We hypothesized that PC exploits PD-1/PD-L1 not only to avoid immune responses …

Background Pancreatic cancer is characterized by a highly immunosuppressive tumor
microenvironment and evasion of immune surveillance. Although programmed cell death 1 …

Although gemcitabine is currently the best chemotherapeutic agent available for the
treatment of advanced pancreatic cancer, eventual failure of response is a significant clinical …

Niclosamide, a cell-permeable salicylanilide, was approved by the Food and Drug
Administration for its anthelmintic efficiency. A growing body of evidence in recent years …